Ovarian Cancer Clinical Trials in Fairfax, Virginia

31 studies are recruiting for ovarian cancer in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   6 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

2. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

   The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Clinical Study Site, Fairfax, Virginia

   Locations

   3 in total

   Run by

   Crescent Biopharma, Inc.

   See if you can join NCT07909031 on ClinicalTrials.gov

3. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   20 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

4. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Fairfax, Virginia

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

5. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   88 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

6. A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

   The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommen…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Phrontline Biopharma

   See if you can join NCT07778498 on ClinicalTrials.gov

7. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute, Fairfax, Virginia

   Locations

   198 in total

   Run by

   Incyte Corporation

   See if you can join NCT07214779 on ClinicalTrials.gov

8. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

9. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 as a monotherapy and in combination with bevacizumab (or a …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   11 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

10. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax, Virginia

    Locations

    198 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

11. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

    Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. Thi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Virginia /ID# 278607, Fairfax, Virginia

    Locations

    27 in total

    Run by

    AbbVie

    See if you can join NCT07278336 on ClinicalTrials.gov

12. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax, Virginia

    Locations

    167 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07318558 on ClinicalTrials.gov

13. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage

    Phase 1

    Ages

    18 to 130

    Site

    Research Site, Fairfax, Virginia

    Locations

    60 in total

    Run by

    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov

14. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Virginia, Fairfax, Virginia

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

15. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

16. A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

    A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 04, Fairfax, Virginia

    Locations

    3 in total

    Run by

    TwoStep Therapeutics, Inc.

    See if you can join NCT07814248 on ClinicalTrials.gov

17. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

18. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    74 in total

    Run by

    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

19. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology Virginia, Fairfax, Virginia

    Locations

    29 in total

    Run by

    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

20. Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

    This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Fairfax, Virginia

    Locations

    6 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07755436 on ClinicalTrials.gov

21. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Normunity Investigational Site, Fairfax, Virginia

    Locations

    18 in total

    Run by

    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

22. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    12 in total

    Run by

    Whitehawk Therapeutics, Inc.

    See if you can join NCT07444814 on ClinicalTrials.gov

23. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #112, Fairfax, Virginia

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

24. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    522, Fairfax, Virginia

    Locations

    49 in total

    Run by

    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

25. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov